St. Jude Medical
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict St. Jude Medical's revenues will wither -2.8% and EPS will expand 3.8%.
The average estimate for revenue is $1.34 billion. On the bottom line, the average EPS estimate is $0.81.
Last quarter, St. Jude Medical logged revenue of $1.41 billion. GAAP reported sales were 2.5% lower than the prior-year quarter's $1.45 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.88. GAAP EPS of $0.78 for Q2 were 8.3% higher than the prior-year quarter's $0.72 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 74.0%, 50 basis points worse than the prior-year quarter. Operating margin was 26.7%, 10 basis points worse than the prior-year quarter. Net margin was 17.3%, 60 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $5.57 billion. The average EPS estimate is $3.43.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on St. Jude Medical is outperform, with an average price target of $46.65.
Can your portfolio provide you with enough income to last through retirement? You'll need more than St. Jude Medical. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add St. Jude Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of St. Jude Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Textura, St. Jude Medical, and Cliffs Natural Resources Jumped Today
These three stocks defied a sharp decline in the stock market. Find out why.
Why St. Jude Medical, Inc. Acquired a Higher Price Today
Abbott agrees to buy the medical-device maker.
How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?
As a minnow among sharks, Abiomed shares are rightfully volatile. Here's why this Fool expects it to survive and thrive.